Journal
CLINICAL AND EXPERIMENTAL MEDICINE
Volume 20, Issue 3, Pages 329-337Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-020-00620-9
Keywords
Hepatocellular carcinoma; Circulating tumor DNA; Precision medicine
Categories
Funding
- National Natural Science Foundation of China [81472672]
- International Science and Technology Cooperation Project of Shanghai [18410721900]
- Leading Talent Program of Minhang District
Ask authors/readers for more resources
The growing role of precision medicine in hepatocellular carcinoma (HCC) is expected to ameliorate the poor prognosis and high mortality of this highly malignant disease; however, it is faced with challenges such as the low frequency of tissue biopsy. Hence, attention is turning to the circulating tumor DNA (ctDNA), an important component of liquid biopsy. Obtaining molecular information about cancer from blood provides a good prospect in precision oncology including molecular diagnosis, molecular classification, targeted therapy, personalized decision making, and detection of drug-resistance mutations. However, inherent constraints of HCC and ctDNA (like background chronic liver diseases (CLD) and low concentration of ctDNA) along with some technical issues should be well handled and solved before the potential of ctDNA in precision medicine of HCC can be truly realized. In this review, we will focus on the prospects and challenges of ctDNA in HCC precision medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available